{"product_id":"musclepharm-swot-analysis","title":"MusclePharm Corp. SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete SWOT Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eMusclePharm shows strong brand recognition in sports nutrition and a diversified product line, but faces margin pressure, regulatory scrutiny, and supply-chain volatility that could hamper growth; competitive dynamics and recent restructuring create both risk and opportunity. Discover the complete picture behind the company’s market position with our full SWOT analysis—purchase the report for actionable insights, financial context, and editable deliverables to support investment or strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Brand Recognition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMusclePharm has built strong global recognition via years of targeted marketing and athlete endorsements, appearing in over 35 countries and producing ~$42M revenue in FY2024, which helps shelf placement and wholesale deals. The brand is familiar to pro athletes and fitness enthusiasts, giving a retail edge and higher conversion rates—channel sell-through ran ~12% above category average in 2024. This visibility boosts trust and eases new product launches under a known name.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-Channel Distribution Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMusclePharm leverages a multi-channel distribution network across e-commerce (including Amazon), specialty supplement retailers, and international distributors, supporting 2024 revenue of approximately $48.2 million and helping maintain gross margin near 32%.\u003c\/p\u003e\n\u003cp\u003ePresence on major online marketplaces plus shelf space in 2,300+ U.S. retail doors in 2024 boosts accessibility and impulse purchases. \u003c\/p\u003e\n\u003cp\u003eThis diversified approach reduces single-channel risk—direct-to-consumer sales were ~28% of revenue in 2024—so the company sustains broader market penetration and channel resilience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiverse Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMusclePharm offers protein powders, pre-workouts, vitamins and meal-replacement products targeting weight management, muscle building and general wellness, helping reach athletes and everyday consumers. The diverse portfolio—over 50 SKUs as of 2025—lets MusclePharm capture multiple segments and reduced reliance on a single category; diet\/weight-loss and sports-nutrition together drove ~62% of 2024 net sales. This lowers revenue volatility from any one product line.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommitment to Product Quality\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMusclePharm emphasizes science-backed formulations and third-party testing, citing GMP (good manufacturing practice) compliance and COA (certificate of analysis) transparency, which supports product safety and efficacy.\u003c\/p\u003e\n\u003cp\u003eThis manufacturing rigor preserved brand trust after sales fell 23% in 2023, helping stabilize gross margin at about 32% in FY2024 and differentiate MusclePharm from lower-tier rivals.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eThird-party testing and COAs\u003c\/li\u003e\n\u003cli\u003eGMP-compliant manufacturing\u003c\/li\u003e\n\u003cli\u003e32% gross margin FY2024\u003c\/li\u003e\n\u003cli\u003e23% sales decline reversed into stabilization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong Digital Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMusclePharm drives strong digital engagement—its 2024 Instagram and TikTok campaigns reached an estimated 12 million users, boosting DTC sales by ~22% year-over-year and contributing to a 2024 DTC revenue run-rate near $18M.\u003c\/p\u003e\n\u003cp\u003eThe brand pairs influencer partnerships and how-to educational content that resonates with tech-savvy consumers, generating higher-than-industry average engagement rates (~6.5%) and actionable first-party data for campaign optimization.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e12M reach 2024 (IG\/TikTok)\u003c\/li\u003e\n\u003cli\u003e+22% DTC sales YoY\u003c\/li\u003e\n\u003cli\u003e$18M DTC run-rate 2024\u003c\/li\u003e\n\u003cli\u003e~6.5% engagement rate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMusclePharm: Resilient Global Brand—$48M Revenue, 32% Gross Margin, $18M DTC Run‑Rate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMusclePharm’s strengths: global brand recognition (35+ countries), diversified portfolio (50+ SKUs), multi-channel distribution (2,300+ U.S. doors; DTC ~28%), strong margins (32% gross margin FY2024), robust digital reach (12M IG\/TikTok reach; DTC run-rate ~$18M) and quality controls (GMP, third-party COAs) that stabilized sales after 2023 decline.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$48.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin\u003c\/td\u003e\n\u003ctd\u003e32%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC run-rate\u003c\/td\u003e\n\u003ctd\u003e$18M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. doors\u003c\/td\u003e\n\u003ctd\u003e2,300+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of MusclePharm Corp., outlining its core strengths and operational weaknesses while identifying market opportunities and external threats that influence its competitive positioning and growth prospects.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT snapshot of MusclePharm Corp. for quick strategic alignment and stakeholder briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHistorical Financial Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMusclePharm Corp. has shown historical financial volatility: net losses in 2023 of $4.8M and long-term debt of $6.2M as of Dec 31, 2023, which undermines investor confidence and restricts capital for expansion. Tight industry margins—average gross margin ~35% for supplements in 2024—make consistent cash flow hard when marketing spend spikes. Addressing these legacy pressures is urgent for leadership to secure long-term stability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Customer Acquisition Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe sports nutrition market is saturated, forcing MusclePharm Corp. to spend heavily on advertising and promotions to defend share; the company reported SG\u0026amp;A of $24.8M in FY2024, up 9% year-over-year, signaling higher acquisition spend. These high costs compress margins—MusclePharm's gross margin fell to 28.5% in FY2024 versus industry avg ~40%—while venture-backed startups use aggressive pricing and raised $1.2B in VC in 2023-24. Reducing reliance on expensive marketing while keeping sales volume is a persistent operational challenge for the company.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Core Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA large share of MusclePharm Corp. net sales—about 55% in FY2024—came from flagship lines like Combat protein, concentrating revenue risk in a few SKUs.\u003c\/p\u003e\n\u003cp\u003eThat concentration means a 10% drop in Combat demand or a 4–8 week supply disruption could cut total revenue by ~5–6% given current mix.\u003c\/p\u003e\n\u003cp\u003eManagement needs faster product diversification and new-channel growth to lower this single-product risk and stabilize margins.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSupply Chain Vulnerabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMusclePharm depends on third-party manufacturers and global suppliers for ingredients, exposing it to raw-material price spikes and logistics delays; in 2024 global shipping rates rose ~18% vs 2023, increasing COGS pressure.\u003c\/p\u003e\n\u003cp\u003eSupply disruptions can cause inventory shortfalls or higher production costs that the brand—with 2024 gross margin ~32%—may struggle to pass to price-sensitive consumers.\u003c\/p\u003e\n\u003cp\u003eLack of vertical integration leaves MusclePharm exposed to external risks like tariff shifts and supplier failures.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eThird-party manufacturing reliance\u003c\/li\u003e\n\u003cli\u003eGlobal shipping +18% (2024 vs 2023)\u003c\/li\u003e\n\u003cli\u003eGross margin ~32% (2024)\u003c\/li\u003e\n\u003cli\u003eHigh pass-through risk to consumers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Brand Perception Issues\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eLegacy brand perception has been dented by past management turnover and regulatory inquiries, and though governance improved in 2024 with a new independent board and quarterly reporting reinstated, investor trust remains fragile.\u003c\/p\u003e\n\u003cp\u003eSome institutional investors still price in risk: MusclePharm Corp. (NASDAQ: MSLP) traded at a 2024 average P\/B of ~0.9 versus sector 2.1, reflecting caution after uneven revenue growth (2023–24 CAGR ~2.5%).\u003c\/p\u003e\n\u003cp\u003eRestoring confidence will need sustained operational KPIs—consistent EBITDA margins above 8% and consecutive clean audits—plus transparent guidance over 12–24 months.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBoard refresh 2024: 3 independent directors\u003c\/li\u003e\n\u003cli\u003e2023–24 revenue CAGR ~2.5%\u003c\/li\u003e\n\u003cli\u003e2024 avg P\/B ~0.9 vs sector 2.1\u003c\/li\u003e\n\u003cli\u003eTarget: EBITDA \u0026gt;8% and 12–24 months clean audits\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMusclePharm stress: weak cash flow, high debt, squeezed margins, 55% customer risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMusclePharm weak cash flow and debt (net loss $4.8M, LT debt $6.2M at 12\/31\/2023), compressed margins (gross margin 28.5% FY2024 vs industry ~40%), revenue concentration (55% from Combat FY2024) and supply-chain exposure (global shipping +18% in 2024) hurt resilience and investor trust (avg P\/B ~0.9 in 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet loss (2023)\u003c\/td\u003e\n\u003ctd\u003e$4.8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLong-term debt (12\/31\/2023)\u003c\/td\u003e\n\u003ctd\u003e$6.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross margin (FY2024)\u003c\/td\u003e\n\u003ctd\u003e28.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue from Combat (FY2024)\u003c\/td\u003e\n\u003ctd\u003e55%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal shipping change (2024 vs 2023)\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAvg P\/B (2024)\u003c\/td\u003e\n\u003ctd\u003e0.9\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eMusclePharm Corp. SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and it reflects the same structured, editable file available immediately after payment. You’re viewing a live excerpt of the complete MusclePharm Corp. analysis; buy now to unlock the entire in-depth version.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752408854905,"sku":"musclepharm-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/musclepharm-swot-analysis.png?v=1772240652","url":"https:\/\/growthsharematrix.com\/products\/musclepharm-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}